Stoke Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Stoke Therapeutics
STOK Stock  USD 31.91  0.02  0.06%   
Analyzing historical trends in various income statement and balance sheet accounts from Stoke Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Stoke Therapeutics' valuation are summarized below:
Gross Profit
205.6 M
Profit Margin
0.1973
Market Capitalization
1.8 B
Enterprise Value Revenue
7.6812
Revenue
205.6 M
There are currently one hundred twenty fundamental trend indicators for Stoke Therapeutics that can be evaluated and compared over time across competition. We recommend to double-check Stoke Therapeutics' current fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 804.8 M this year. Enterprise Value is expected to rise to about 642.2 M this year

Stoke Therapeutics Total Revenue

44.14 Million

Check Stoke Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Stoke Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 15.3 M, Interest Income of 131.1 K or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 26.26, Dividend Yield of 0.0 or PTB Ratio of 2.46. Stoke financial statements analysis is a perfect complement when working with Stoke Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Stoke Stock
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

Stoke Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets224.3 M312.3 M128.5 M
Slightly volatile
Short and Long Term Debt Total2.3 M2.7 M2.4 M
Slightly volatile
Other Current Liabilities9.5 M18.7 M5.9 M
Slightly volatile
Total Current Liabilities48.4 M46.1 M15.4 M
Slightly volatile
Other Liabilities44.8 M42.7 M12 M
Slightly volatile
Property Plant And Equipment Net6.8 M9.5 M4 M
Slightly volatile
Accounts Payable1.5 M2.9 M949.8 K
Slightly volatile
Cash164.3 M147.2 M89.3 M
Slightly volatile
Non Current Assets Total46.8 M44.6 M10.4 M
Slightly volatile
Non Currrent Assets Other426 K829.1 K279.1 K
Slightly volatile
Other Assets621.6 K654.4 K14.9 M
Pretty Stable
Cash And Short Term Investments204.1 M249.4 M114.8 M
Slightly volatile
Common Stock Shares Outstanding37.4 M62.1 M31.5 M
Slightly volatile
Liabilities And Stockholders Equity224.3 M312.3 M128.5 M
Slightly volatile
Non Current Liabilities Total2.7 M2.8 M5.3 M
Slightly volatile
Capital Surpluse315.1 M555.6 M214.1 M
Slightly volatile
Other Current Assets18.3 M17.4 M5.8 M
Slightly volatile
Other Stockholder Equity869.4 M828 M281.2 M
Slightly volatile
Total Liabilities31.1 M48.9 M19.5 M
Slightly volatile
Property Plant And Equipment Gross20.7 M19.7 M6.4 M
Slightly volatile
Total Current Assets213 M267.7 M120.2 M
Slightly volatile
Non Current Liabilities Other2.1 M2.8 M1.2 M
Slightly volatile
Common Stock3.7 K5.8 K2.6 K
Slightly volatile
Property Plant Equipment4.1 M7.7 M3 M
Slightly volatile
Net Receivables845.2 K805 K305 K
Slightly volatile
Capital Stock4.2 K5.8 K3.1 K
Slightly volatile
Capital Lease Obligations2 M2.7 M1.5 M
Slightly volatile

Stoke Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.6 M2.5 M867.9 K
Slightly volatile
Selling General Administrative58.9 M56.1 M19.3 M
Slightly volatile
Other Operating Expenses166.5 M158.6 M55 M
Slightly volatile
Research Development107.6 M102.5 M35.7 M
Slightly volatile
Cost Of Revenue5.4 M5.1 M1.7 M
Slightly volatile
Total Operating Expenses166.5 M158.6 M55 M
Slightly volatile
Reconciled Depreciation2.6 M2.5 M867 K
Slightly volatile
Non Operating Income Net Other295.5 K150.3 K582.2 K
Slightly volatile
Selling And Marketing Expenses1.8 M2 M2.2 M
Slightly volatile

Stoke Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock909.7 K957.6 K25.3 M
Very volatile
Stock Based Compensation33.2 M31.6 M9.7 M
Slightly volatile
Begin Period Cash Flow147.2 M220.8 M85.2 M
Slightly volatile
Depreciation2.6 M2.5 M867.9 K
Slightly volatile
Other Non Cash Items914.1 K716.5 K488.6 K
Slightly volatile
Capital Expenditures221.8 K233.4 K703.5 K
Slightly volatile
Total Cash From Financing Activities84.1 M150.8 M52.2 M
Slightly volatile
End Period Cash Flow164.7 M148.1 M89.6 M
Slightly volatile
Change To Netincome27.6 M26.3 M8.7 M
Slightly volatile
Change To Liabilities58.2 M55.4 M15.9 M
Slightly volatile
Issuance Of Capital Stock72.5 M116 M103 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio26.2618.7427.2881
Slightly volatile
Days Sales Outstanding9.888.0414.852
Slightly volatile
Stock Based Compensation To Revenue0.820.861.7211
Slightly volatile
Capex To Depreciation0.10.112.8759
Slightly volatile
EV To Sales13.7914.7917.9964
Slightly volatile
Payables Turnover1.221.160.943
Slightly volatile
Sales General And Administrative To Revenue1.461.542.9313
Slightly volatile
Research And Ddevelopement To Revenue2.662.85.8138
Slightly volatile
Capex To Revenue0.00610.00640.2561
Slightly volatile
Cash Per Share4.63.613.2201
Slightly volatile
Days Payables Outstanding310326478
Pretty Stable
Income Quality0.891.120.897
Slightly volatile
Current Ratio6.356.6810.2917
Pretty Stable
Receivables Turnover56.1447.033.3417
Slightly volatile
Capex Per Share0.00320.00340.0225
Slightly volatile
Revenue Per Share0.320.610.3501
Slightly volatile
Interest Debt Per Share0.06440.04940.0836
Slightly volatile
Debt To Assets0.00930.00980.5825
Slightly volatile
Operating Cycle9.888.0414.852
Slightly volatile
Days Of Payables Outstanding310326478
Pretty Stable
Ebt Per Ebit1.051.010.9819
Slightly volatile
Total Debt To Capitalization0.0110.01150.831
Slightly volatile
Quick Ratio6.356.6810.2917
Pretty Stable
Cash Ratio3.493.679.0957
Pretty Stable
Days Of Sales Outstanding9.888.0414.852
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.151.0462
Slightly volatile
Fixed Asset Turnover4.193.991.6133
Slightly volatile
Debt Ratio0.00930.00980.5825
Slightly volatile
Price Sales Ratio26.2618.7427.2881
Slightly volatile
Asset Turnover0.130.120.0619
Slightly volatile

Stoke Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap804.8 M685.1 M679.5 M
Very volatile
Enterprise Value642.2 M540.6 M592.3 M
Very volatile

Stoke Fundamental Market Drivers

Forward Price Earnings204.0816
Cash And Short Term Investments216.9 M

Stoke Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Stoke Therapeutics Financial Statements

Stoke Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Stoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.8 M22.9 M
Total Revenue42 M44.1 M
Cost Of Revenue5.1 M5.4 M
Stock Based Compensation To Revenue 0.86  0.82 
Sales General And Administrative To Revenue 1.54  1.46 
Research And Ddevelopement To Revenue 2.80  2.66 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.61  0.32 
Ebit Per Revenue(2.50)(2.62)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:
How To Invest In Stoke
Details
Is Stoke Stock a good investment?
Details
What is Stoke Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Stoke Therapeutics Correlation against competitors.
For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
0.68
Revenue Per Share
3.547
Quarterly Revenue Growth
1.172
Return On Assets
0.052
Return On Equity
0.1502
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY